Perrigo, a major consumer health company, has agreed to sell its infant formula business to MeridianMade, a private contract manufacturer, in a deal valued at up to $175 million. The transaction includes $40 million paid at closing, with additional earn-out payments tied to the business's performance through 2030.
The sale marks a strategic shift for Perrigo, which is narrowing its portfolio to concentrate on over-the-counter (OTC) health products—the kind of medicines and remedies you can buy without a prescription, such as pain relievers, cough syrups, and digestive aids.
Why Perrigo is selling
Perrigo has been reshaping its business for years, shedding divisions that don't align with its core focus. Infant formula, while a staple in many households, operates in a highly regulated and competitive market, with strict quality standards and thin margins. By divesting this unit, Perrigo can redirect capital and management attention toward its OTC lineup, which tends to offer more consistent demand and potentially better profitability.
The earn-out structure is notable. Instead of receiving the full $175 million upfront, Perrigo gets $40 million now and the rest depends on how the infant formula business performs over the next several years. This arrangement is common in deals where the buyer wants to hedge against uncertainty, and the seller is willing to bet on future results. For Perrigo, it means the final price tag could be lower if the business underperforms, but it also gives MeridianMade an incentive to keep the operation running smoothly.
MeridianMade, as a contract manufacturer, likely plans to continue producing infant formula for existing customers or to integrate the business into its broader manufacturing operations. The deal does not include any public details about the brand names or specific products involved, but the sale is expected to close in the coming months, subject to regulatory approvals.
What it means for investors
For everyday investors, this sale is a signal about Perrigo's direction. The company is betting that a leaner, more focused OTC business will deliver better returns than a sprawling portfolio that included infant formula. That's a strategy many companies pursue when they want to simplify operations and appeal to investors who prefer clarity over complexity.
The $40 million upfront payment is a modest sum for a company of Perrigo's size, but the earn-outs could add meaningful value if the infant formula business hits its targets. Investors should watch for updates on those performance milestones, as they will determine the final sale price.
This deal also fits a broader trend in the consumer health sector, where companies are increasingly shedding non-core assets to focus on higher-growth categories. The supplement and wellness space, in particular, has seen a wave of consolidation, as companies look to capitalize on growing consumer interest in preventive health.
For Perrigo shareholders, the key question is whether the OTC focus will translate into stronger sales and margins. The company has faced headwinds in recent years, including supply chain disruptions and competition from private-label brands. By streamlining its operations, Perrigo hopes to improve its competitive position and generate more predictable cash flows.
Looking ahead
The sale is expected to close in the near term, and investors will be watching for any regulatory hurdles. The earn-out payments, tied to performance through 2030, mean that Perrigo's financial results could see occasional boosts or shortfalls depending on how the infant formula business fares under new ownership.
For those who own Perrigo stock, this deal is a reminder that corporate strategy can have a direct impact on shareholder value. Divestitures can unlock value by removing underperforming units, but they also reduce revenue, so the net effect depends on how efficiently the company deploys the proceeds.
In the broader market, this transaction is a relatively small one, but it highlights the ongoing shift toward operational focus that investors are demanding across industries. Just as tech giants are being judged on cash flow rather than growth at any cost, consumer health companies are being pushed to prove that every division earns its place.
Perrigo's move also echoes similar divestitures in other sectors, such as Bell Canada selling a stake in its tower business to raise capital and streamline operations. The pattern is consistent: companies are simplifying to stay competitive in a fast-changing economic environment.
For now, the deal is a positive step for Perrigo's strategic clarity, but the real test will come in the years ahead as the earn-outs play out and the OTC business proves its growth potential. Investors should keep an eye on Perrigo's quarterly reports for any updates on the sale's progress and the performance of its remaining portfolio.
